AwardedSpainGoodsFramework agreement€319,770
Adjudicación del Contrato Basado del Acuerdo Marco del Suministro de MEDICAMENTOS PARA EL TRATAMIENTO DE LA HIPERCOLESTEROLEMIA PRIMARIA (FAMILIAR HETEROZIGÓTICA Y NO FAMILIAR) O DISLIPEMIA MIXTA CON INHIBIDORES DE PCSK9, del Consorci Sanitari Integral
- Published
- Published 2 June 2026
Overview
The Consorci Sanitari Integral awarded a contract on 1 June 2026 for the supply of medicines to treat primary hypercholesterolaemia (familial heterozygous and non-familial) or mixed dyslipidaemia with PCSK9 inhibitors, valued at approximately €319,770. The contract was awarded to Amgen, S.A. and Sanofi Aventis, S.A.
Key details
- Country
- Spain
- Status
- Awarded
- Category
- Goods
- Estimated value
- €319,770
- Procedure
- Open
- Contract type
- Framework agreement
- Published
- 2 June 2026
Pharmaceutical products
Award outcome
- Award date
- 1 June 2026
- Contract period
- 1 June 2026 → 27 May 2027
- AMGEN, S,A,
- Sanofi Aventis, S,A,
Contract ending soon? Skim tracks incumbents and flags recompetes early. Book a demo to set up alerts.
Notice history
Every published notice in this contracting process, newest first.
Contract Award Notice
2 June 2026
Contracting authority
Consorci Sanitari Integral
Procuring entityL’Hospitalet de Llobregat, Spain
Get the full picture
AI analysis, bid scoring, and expert strategy for this tender
Skim analyses every tender against your company profile and tells you whether to bid, how to win, and who you are up against.
See which competitors are winning the contracts you're chasing.
15-minute call. We'll pull the win data on your real pipeline and show you what Skim does with it.